share_log

HUTCHMED Confirms ELUNATE And SULANDA Remain On China's National Reimbursement Drug List Under Existing Terms

Benzinga ·  Dec 13, 2023 01:44

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration ("NHSA"), on January 1, 2024 the updated National Reimbursement Drug List ("NRDL") will continue to include ELUNATE (fruquintinib) and SULANDA (surufatinib) at the same terms as the current two-year agreement.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment